HealthCap

Rampart Bioscience Announces $85M Series A Financing to Develop Novel DNA-Based Medicines with Veteran Team

Retrieved on: 
Tuesday, October 24, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, OrbiMed, Hypophosphatasia, Alexion, HealthCap, General partnership, MBA, Electro-technical officer, Code, HPP, Disease, CSL Behring, Safety, HALO, Patient, DNA, Vaccine, Pharmaceutical industry, Rampart

Rampart Bioscience, Inc., a biotechnology company developing next-generation biologics, today announced an $85 million Series A financing to create medicines that aim to unburden patients from disease and their treatments.

Key Points: 
  • Rampart Bioscience, Inc., a biotechnology company developing next-generation biologics, today announced an $85 million Series A financing to create medicines that aim to unburden patients from disease and their treatments.
  • The new financing builds on an initial $40 million seed investment from OrbiMed.
  • The Rampart team has tremendous heart and a fierce commitment to reshaping the treatment landscape for those in dire need of better options,” said Louis Breton, Rampart Co-founder, Chief Executive Officer, and Board Director.
  • “Rampart’s DNA medicines contain novel structural elements that drive nuclear trafficking and retention while avoiding immune responses,” said Jeffrey Bartlett, Ph.D., Rampart Co-founder and Chief Innovation and Technical Officer.

Three Gardant Management Solutions Communities Achieve 2023 AHCA/NCAL Silver National Quality Award

Retrieved on: 
Friday, June 30, 2023
HealthCap, First Quality, Assisted living, Malcolm Baldrige National Quality Award, Silver Award, Heritage Woods Secondary School, PharMerica, Nursing, Ironworks, Charge (heraldry), Convention

BOURBONNAIS, Ill., June 30, 2023 /PRNewswire-PRWeb/ -- Three Gardant-managed affordable assisted living communities were among eight assisted living communities nationally to be named recipients of a 2023 Silver Achievement in Quality Award from the American Health Care Association/National Center for Assisted Living.

Key Points: 
  • Three Gardant-managed affordable assisted living communities were among eight assisted living communities nationally to be named recipients of a 2023 Silver Achievement in Quality Award from the American Health Care Association/National Center for Assisted Living.
  • BOURBONNAIS, Ill., June 30, 2023 /PRNewswire-PRWeb/ -- Three Gardant-managed affordable assisted living communities were among eight assisted living communities nationally to be named recipients of a 2023 Silver Achievement in Quality Award from the American Health Care Association/National Center for Assisted Living.
  • "We are extremely proud of these Gardant-managed communities for being named recipients of a 2023 Silver Award," says Alexandra Shuell, Vice President of Operations for Gardant Management Solutions, Inc. "The award recognizes communities that have reached a standard of excellence in quality based on the Baldrige Excellence Framework."
  • The 2023 National Quality Award program is sponsored by AHCA/NCAL Associate Business Members PharMerica, Pinnacle Quality Insight, Prevail by First Quality, HealthCap, and Matrix Care.

Spruce Biosciences Reports Full Year 2022 Financial Results and Provides Corporate Updates

Retrieved on: 
Thursday, March 16, 2023
Biotechnology, General Health, Pharmaceutical, Health, Investment, Silicon Valley Bank, PCOS, Strategic partnership, Depreciation, Trial of the century, Androstenedione, Novo Holdings A/S, Public expenditure, CAH, Administration, Polycystic ovary syndrome, Patient, G&A, Spruce, Safety, A4, Research and development, R, Pharmaceutical industry, Cryptocurrency, Adult, HealthCap, Cycloheximide

(Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2022 and provided corporate updates.

Key Points: 
  • (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2022 and provided corporate updates.
  • “In 2022, we made significant progress across the board heading into 2023, which we believe will be a pivotal year for Spruce,” said Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce Biosciences.
  • Stock-based compensation expense for the year ended December 31, 2022 was $3.6 million compared to $4.0 million in 2021.
  • Net Loss: Net loss for the year ended December 31, 2022 was $46.2 million compared to $42.3 million in 2021.

Carisma Therapeutics Closes Merger with Sesen Bio

Retrieved on: 
Tuesday, March 7, 2023
Shearman, University of Pennsylvania Health System, Symbiosis, SVB, Patient, SVB Securities, AbbVie, HealthCap, Shearman & Sterling, Growth, Sale, CARM, Therapy, Solasta: Crown of the Magister, Wellington Partners, Cancer, Merck & Co., BofA Securities, Immunotherapy, Caregiver, Wilmer Cutler Pickering Hale and Dorr, Merck, Cryptocurrency, Nursing, Management, Mitsubishi Carisma

PHILADELPHIA, March 7, 2023 /PRNewswire/ -- Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, and Sesen Bio, Inc. ("Sesen Bio"), announced today the closing of their previously announced merger. The combined company will operate under the name Carisma Therapeutics Inc. and shares of its common stock will commence trading under the ticker symbol "CARM" on March 8, 2023 on the Nasdaq Capital Market.

Key Points: 
  • Shares of Carisma to commence trading on Nasdaq under new ticker symbol "CARM" on March 8, 2023
    Resulting cash position of approximately $140 million provides runway through 2024; expected to enable multiple clinical readouts across Carisma programs
    PHILADELPHIA, March 7, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. , a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, and Sesen Bio, Inc. ("Sesen Bio"), announced today the closing of their previously announced merger.
  • Dr. Thomas Cannell, President and Chief Executive Officer of Sesen Bio, said, "I want to thank the entire Sesen Bio team for their steadfast commitment to our mission to save and improve lives.
  • Patients, caregivers and investigators around the world have been important advocates of Sesen Bio and I want to thank them for their support.
  • SVB Securities acted as the exclusive financial advisor to Sesen Bio for the transaction, and Hogan Lovells US LLP served as Sesen Bio's legal counsel.

Spruce Biosciences Announces $53.6 Million Private Placement Financing

Retrieved on: 
Thursday, February 9, 2023
Biotechnology, Health, Science, Pharmaceutical, Research, Public expenditure, Novo Holdings A/S, CAH, Sale, SVB Securities, Congenital adrenal hyperplasia, Security (finance), HealthCap

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that it has entered into a definitive securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $53.6 million, before deducting offering expenses.

Key Points: 
  • Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that it has entered into a definitive securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $53.6 million, before deducting offering expenses.
  • The private placement includes participation from new and existing investors, including 5am Ventures, Abingworth, Armistice Capital, HealthCap, Novo Holdings A/S, RiverVest Venture Partners, and Rock Springs Capital.
  • The pre-funded warrants and accompanying warrants will be exercisable for a period of five years following the date of issuance.
  • SVB Securities is acting as the placement agent for the financing.

Oncopeptides has announced the Nomination Committee

Retrieved on: 
Thursday, December 22, 2022
Patient, Person, Nasdaq Stockholm, Multiple myeloma, Melphalan flufenamide, Transplant, Notice, Disease, Hematologic disease, Marketing, HealthCap, FDA, Union, Committee, Dexamethasone, Corporate communication, HIV disease progression rates, PDC, Letter, Research, Whaling, Pharmaceutical industry

According to the principles for the appointment of the Nomination Committee in Oncopeptides AB (publ), the Nomination Committee for the annual general meeting 2023 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of September 30 who are willing to participate in the Nomination Committee, along with the Chairman of the Board of Directors.

Key Points: 
  • According to the principles for the appointment of the Nomination Committee in Oncopeptides AB (publ), the Nomination Committee for the annual general meeting 2023 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of September 30 who are willing to participate in the Nomination Committee, along with the Chairman of the Board of Directors.
  • The composition of the Nomination Committee has now been established, and Oncopeptides today announced that the Nomination Committee in respect of the annual general meeting 2023 consists of the following persons who together represent approximately 29 percent of the number of shares and votes in the company based on the shareholder information at end of September.
  • The Nomination Committee's proposals will be presented in the Notice to the annual general meeting 2023 and on Oncopeptides' website, www.oncopeptides.com .
  • Shareholders who wish to submit proposals to the Nomination Committee can do so by sending an e-mail to [email protected] (subject "Nomination Committee") or by letter posted to Oncopeptides AB (publ), Attn: Oncopeptides Nomination Committee, Luntmakargatan 46, SE-111 37 Stockholm, Sweden.

Oncopeptides has announced the Nomination Committee

Retrieved on: 
Thursday, December 22, 2022
Patient, Person, Nasdaq Stockholm, Multiple myeloma, Melphalan flufenamide, Transplant, Notice, Disease, Hematologic disease, Marketing, HealthCap, FDA, Union, Committee, Dexamethasone, Corporate communication, HIV disease progression rates, PDC, Letter, Research, Whaling, Pharmaceutical industry

According to the principles for the appointment of the Nomination Committee in Oncopeptides AB (publ), the Nomination Committee for the annual general meeting 2023 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of September 30 who are willing to participate in the Nomination Committee, along with the Chairman of the Board of Directors.

Key Points: 
  • According to the principles for the appointment of the Nomination Committee in Oncopeptides AB (publ), the Nomination Committee for the annual general meeting 2023 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of September 30 who are willing to participate in the Nomination Committee, along with the Chairman of the Board of Directors.
  • The composition of the Nomination Committee has now been established, and Oncopeptides today announced that the Nomination Committee in respect of the annual general meeting 2023 consists of the following persons who together represent approximately 29 percent of the number of shares and votes in the company based on the shareholder information at end of September.
  • The Nomination Committee's proposals will be presented in the Notice to the annual general meeting 2023 and on Oncopeptides' website, www.oncopeptides.com .
  • Shareholders who wish to submit proposals to the Nomination Committee can do so by sending an e-mail to [email protected] (subject "Nomination Committee") or by letter posted to Oncopeptides AB (publ), Attn: Oncopeptides Nomination Committee, Luntmakargatan 46, SE-111 37 Stockholm, Sweden.

Ariceum Therapeutics and AmbioPharm Enter Strategic Manufacturing and Supply Partnership

Retrieved on: 
Thursday, October 27, 2022
Biotechnology, Manufacturing, Health, Radiology, Pharmaceutical, Oncology, Other Science, Research, Other Manufacturing, Science, Clinical Trials, Biotechnology, LSP, Peptide, Polonium, CGMP, Neoplasm, Squamous cell carcinoma, Radium, Doctor of Philosophy, FDA, CDMO, Therapy, NETS, SCLC, Partnership, Radiopharmaceutical, Research, HealthCap, API, Cancer, SST2, Diagnosis, Neuroblastoma, Fine chemical, Medical imaging, Ipsen

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and systemic targetedradiation therapy of certain hard-to-treat cancers, and AmbioPharm, a global peptide contract development and manufacturing organization, today announce that they have entered into a strategic partnership for the manufacture and supply of peptide conjugates to be used by Ariceum in future clinical studies.

Key Points: 
  • Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and systemic targetedradiation therapy of certain hard-to-treat cancers, and AmbioPharm, a global peptide contract development and manufacturing organization, today announce that they have entered into a strategic partnership for the manufacture and supply of peptide conjugates to be used by Ariceum in future clinical studies.
  • AmbioPharm is supporting Ariceum with cGMP manufacturing and supply of peptide conjugates that will be radio-labelled as the radiopharmaceutical end-product used in upcoming clinical trials.
  • Manfred Rdiger, PhD, Chief Executive Officer of Ariceum Therapeutics, said: Ariceum is very pleased to be partnering with AmbioPharm.
  • Ariceum Therapeutics (Ariceum) is a private, clinical stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers.

Pretzel Therapeutics Launches With $72.5 Million Series A Financing to Pioneer Mitochondrial Therapies

Retrieved on: 
Monday, September 12, 2022
Biotechnology, Genetics, Health, Lists of diseases, MRC Mitochondrial Biology Unit, Senior advisor, Ageing, Industry, Business, Salk Institute for Biological Studies, ROME, Drug development, ISCB Senior Scientist Award, HealthCap, Plasma protein binding, Degenerative disease, Enzyme, Mitochondrial disease, Coronavirus Scientific Advisory Board (Turkey), Norwest Venture Partners, IPO, MBA, Praxis, University of Cambridge, DNA, Karolinska Institute, MRC, Chemistry (relationship), Senior, Biotechnology, AstraZeneca, University of Gothenburg, Roberto Minczuk, Board, Biophysics, Business development, Genome, Drug discovery, Therapy, Department, MA, GV, Vertex Pharmaceuticals, Laboratory, Pretzel, University, Pharmaceutical industry, Management, Director, Genetics, U.S. Venture Partners, Chemistry, DRS

Pretzel Therapeutics , a biotechnology company harnessing the intricacies of mitochondrial biology to develop groundbreaking therapies, launched today with a $72.5 million Series A financing to pioneer novel therapies to modulate mitochondrial function.

Key Points: 
  • Pretzel Therapeutics , a biotechnology company harnessing the intricacies of mitochondrial biology to develop groundbreaking therapies, launched today with a $72.5 million Series A financing to pioneer novel therapies to modulate mitochondrial function.
  • We are excited to pioneer a new era in the treatment of diseases related to mitochondrial dysfunction.
  • Pretzels platform encompasses three primary technologies to modulate mitochondrial function: Genome correction, genome expression modulation, and mitochondrial quality control.
  • The companys genome correction therapeutics will utilize specialized gene-editing tools to reduce mutated mitochondrial DNA and increase the levels of healthy mitochondrial DNA.

Ariceum Therapeutics Appoints Chief Business Officer

Retrieved on: 
Thursday, July 7, 2022
Diagnosis, SCLC, Wilms' tumor, Serge, Business, Polonium, Merck Group, Neuroblastoma, Cancer, Industry, SST2, Radium, Therapy, Drugs for Neglected Diseases Initiative, NETS, List of life sciences, University, Squamous cell carcinoma, Doctor of Philosophy, HealthCap, Debiopharm, LSP, Radiopharmaceutical, Neoplasm, University of Tours, Pharmaceutical industry, Ipsen, Takeda

BERLIN, July 7, 2022 /PRNewswire/ --Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and systemic targetedradiation therapy of certain hard-to-treat cancers, is pleased to announce the appointment of Serge Sagodira as Chief Business Officer.

Key Points: 
  • BERLIN, July 7, 2022 /PRNewswire/ --Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and systemic targetedradiation therapy of certain hard-to-treat cancers, is pleased to announce the appointment of Serge Sagodira as Chief Business Officer.
  • Manfred Rdiger, PhD, Chief Executive Officer of Ariceum Therapeutics, said: "We are delighted to have attracted such a high calibreindividual for this important role.
  • Serge Sagodira, new Chief Business Officer of Ariceum Therapeutics, added: "I am excited to be taking on this new role, working with a team of experienced industry professionals to advance products that I believe have the potential to transform the treatment of very challenging cancers and ultimately significantly improve patient outcomes.
  • Ariceum Therapeutics (Ariceum) is a private, clinical stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers.